Jheng‐Yan Wu

Psychiatric Safety of GLP ‐1 and Dual GIP / GLP ‐1 Receptor Agonists in Adolescents With Obesity

Tinghui Liu, Yang‐Li Shen, Tien‐Hsiang Kuo, Jheng‐Yan Wu et autres

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1 receptor agonists are increasingly used for adolescent obesity, but concerns persist regarding psychiatric adverse events, particularly suicidality. METHODS: This retrospective cohort study used deidentified electronic health records from the TriNetX Global Collaborative Network. …

tw (code pays fourni par la source)

Tirzepatide and the risk of asthma exacerbations in patients with type 2 diabetes

Kuang‐Ming Liao, Chia-Yu Kuo, Jheng‐Yan Wu, Wan‐Hsuan Hsu et autres

Background: Tirzepatide (TZP), a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, demonstrates anti-inflammatory properties that may benefit patients with asthma and type 2 diabetes (T2D). We sought to assess the comparative effectiveness of TZP versus other antidiabetic agents …

tw (code pays fourni par la source)

GLP-1 receptor agonists versus SGLT2 inhibitors in patients with coexisting COPD and heart failure

Sheng-Chi Huang, Jheng‐Yan Wu, Chia-Yu Kuo, Wan‐Hsuan Hsu et autres

Chronic obstructive pulmonary disease (COPD) and heart failure (HF) frequently coexist, leading to elevated risks of morbidity and mortality. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium–glucose cotransporter 2 inhibitors (SGLT2is) have demonstrated cardiopulmonary benefits, but their comparative effectiveness in patients with both …

tw (code pays fourni par la source)

Glucagon-like Peptide-1 Receptor Agonists and Risk of Tuberculosis in Type 2 Diabetes

Kuang‐Ming Liao, Jheng‐Yan Wu, Chih‐Cheng Lai

Tuberculosis remains a leading cause of illness and death worldwide, and individuals with type 2 diabetes have an increased risk of developing this infection. However, whether different glucose-lowering medications influence this risk is unclear. Here we show that use of glucagon-like peptide-1 …

tw (code pays fourni par la source)

Risk of falls and delirium associated with dual orexin receptor antagonists versus benzodiazepines and Z-drugs in older adults with dementia

Ting-Hui Liu, Chia-Chun Chu, Chia-Yu Liu, Jheng‐Yan Wu et autres

Insomnia in older adults with dementia is commonly treated with benzodiazepines (BZDs) and Z drugs, despite safety concerns. Evidence on dual orexin receptor antagonists (DORAs) in this population remains limited. Therefore, this study aimed to compare safety outcomes of DORAs versus BZDs/Z …

tw (code pays fourni par la source)

Perfusion-guided thrombolysis beyond 4.5 hours for acute ischemic stroke: A time-stratified systematic review and meta-analysis

Wen-Wen Tsai, Kuan-Hsien Lu, Kuan-Hung Lin, Jheng‐Yan Wu et autres

Introduction In the contemporary endovascular thrombectomy (EVT) era, treatment decisions are often made without routine perfusion imaging. However, perfusion remains central to intravenous thrombolysis (IVT) beyond 4.5 hours. Evidence across extended and very late windows remains uncertain. Objectives To evaluate the efficacy …

tw (code pays fourni par la source)

Risk of Bone Mineral Density Loss Associated with GLP-1 Receptor Agonists in Overweight COPD Populations [Response to Letter]

Sheng-Chi Huang, Jheng‐Yan Wu, Chia-Yu Kuo, Wan‐Hsuan Hsu et autres

We thank Hong and Liu for their thoughtful comments on our article examining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and clinical outcomes in patients with chronic obstructive pulmonary disease (COPD) and obesity. 1 Their letter raises two points: the lack of an osteoporosis-and …

tw (code pays fourni par la source)

Comparative effectiveness of finerenone versus steroidal mineralocorticoid receptor antagonists on sepsis-induced cardiomyopathy in patients with diabetic kidney disease: a real-world cohort study

Jheng‐Yan Wu, Keng-Wei Lee, Sheng-Chi Huang, Hsuan-Yuan Chang et autres

Background: Sepsis-induced cardiomyopathy (SICM) is a common but underrecognized complication of sepsis and is associated with adverse short- and long-term outcomes. Patients with diabetic kidney disease (DKD) are particularly vulnerable to sepsis-related cardiac dysfunction, potentially due to chronic inflammation and heightened mineralocorticoid …

tw, us, de (code pays fourni par la source)

Comparative Cardiovascular Outcomes of Tirzepatide and Glucagon‐Like Peptide‐1 Receptor Agonists in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

Jheng‐Yan Wu, Keng-Wei Lee, Chia‐Li Kao, Kuo‐Chuan Hung et autres

BACKGROUND: To evaluate the association between tirzepatide use and 1-year risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease, compared with GLP-1 (glucagon-like peptide-1) receptor agonists. METHODS: We conducted a retrospective, propensity score-matched cohort study …

tw (code pays fourni par la source)

Corrigendum to ‘Liberal vs. restrictive transfusion strategy for acute brain injury: a meta-analysis with trial sequential analysis of randomized clinical trials’

Wen-Wen Tsai, Jheng‐Yan Wu, Kuan-Hsien Lu, Hong-Xiang Zheng et autres

tw (code pays fourni par la source)

Association Between Sacubitril/Valsartan Use and Risk of Major Adverse Cardiovascular Events in Patients With Durable Left Ventricular Assist Devices: A Multi‐Institutional Real‐World Cohort Study

Jheng‐Yan Wu, Keng-Wei Lee, S H. M. Huang, Yu‐Min Lin

Background Durable left ventricular assist devices improve survival in patients with advanced heart failure (HF), yet long‐term outcomes remain limited by recurrent decompensation and end‐organ dysfunction. Evidence on the prognostic association of angiotensin receptor–neprilysin inhibitor (ARNI) therapy after left ventricular assist device …

tw (code pays fourni par la source)

Direct-Acting Antiviral Therapy and Long-Term Outcomes in Dialysis Patients With Hepatitis C: A Real-world Cohort Study

Ming‐Yan Jiang, Jheng‐Yan Wu, Yi-Chan Lee, Tsung‐Hsueh Lu

Background: Hepatitis C virus (HCV) infection is associated with adverse outcomes among patients with end-stage kidney disease (ESKD) receiving dialysis. Although direct-acting antivirals (DAAs) achieve high cure rates in patients with ESKD, real-world evidence regarding their long-term clinical benefits remains limited. We …

tw (code pays fourni par la source)